Seeking Alpha Digest
The Daily Alpha
Tuesday, September 1, 2026 · 41 articles
Today's Seeking Alpha analysis, distilled to keywords. Updated every morning.
- AI CapEx = 35-65% of Q1 GDP growth
- Fed: investment strength is AI infra
- High-tech capex 39.9% -> 6.9% QoQ
- Too early to call buildout slowdown
- Author neutral: cash over equities
Read on Seeking Alpha →
- Risk = bonds, not stocks
- Oil $90-100 + deficits squeeze Fed
- Japan yields: Treasury demand threat
- Long-term constructive, near-term underpriced bond risk
Read on Seeking Alpha →
- Fed hawkish: hikes still on table
- Worst bond selloff since 2007
- Yields up if inflation >2.5%
- S&P 500 year-end target: 8,000
- September = volatility
Read on Seeking Alpha →
- Shiller PE 42, near dot-com peak
- Fed easing = policy error
- Yield-curve reinversion risk
- Slow Fed = long rates spike
Read on Seeking Alpha →
- Quiet QE since February
- Accumulation slowed, negative in August
- Yields rangebound 3.25-4.75% since 2022
- Warsh: Fed ready to fight inflation
Read on Seeking Alpha →
- Treasury doubles buyback sizes
- Gold +15%, Bitcoin +25% in August
- 6 months of unwinding reversed
- Financial repression playbook
Read on Seeking Alpha →
- Interest coverage robust in IG + HY
- CCC borrowers: refi rates could double
- Late-cycle headwinds for weak balance sheets
Read on Seeking Alpha →
- 7 countries' election-market study
- Reactions far from uniform
- Less extreme than pundits predict
Read on Seeking Alpha →
- Q2 beat-and-raise, AI demand intact
- Watch: margins, supply commitments
- Stock compressed at range top
- Full-stack AI = core infrastructure
Read on Seeking Alpha →
- Semis leading growth stocks
- Concentration risk redrawing map
Read on Seeking Alpha →
- Upgrade to Buy
- Q2: +30% YoY revenue
- Sept guide: +52% rev, +71% EPS
- AI + memory demand, lower China risk
Read on Seeking Alpha →
- Memory ETF upgraded to Buy
- 35%+ Samsung + SK Hynix
- 6x earnings
- Supply constraints support pricing
Read on Seeking Alpha →
- Upgrade to Buy
- Q2: +32% revenue YoY
- Gold subscriptions +54%
- Catalysts: crypto, prediction markets, banking
Read on Seeking Alpha →
- AI ad platform pivot
- Ads + Vector: +38% YoY
- EBITDA margin 29%, guiding 33%
- Buy: 15-20% upside
Read on Seeking Alpha →
- US commercial = next bull leg
- Army TITAN AI systems deal
Read on Seeking Alpha →
- 2028 oversupply risk fading
- Memory cycle support
Read on Seeking Alpha →
- Upgrade after Q2
- Delivery + margin momentum
Read on Seeking Alpha →
- Q2: +7% revenue, +16% EPS
- Pricing power intact
- 27x P/E = thin margin of safety
- Hold rating
Read on Seeking Alpha →
- Counter view: Sell, $63 target
- ~30% downside call
- Growth = weather, World Cup, FX
- Re-entry: $65-68
Read on Seeking Alpha →
- Card network -> trust/services layer
- Yield compression in mix
- Fair value $368 vs $382 price
Read on Seeking Alpha →
- $1.8B AI orders in Q2
- FY26 guide: $2B+ AI networking
- Neutral until margin quality proven
Read on Seeking Alpha →
- Buy: sole Navy reactor maker
- Backlog $8.4B
- Commercial nuclear +45% FY26 guide
- AI power demand tailwind
Read on Seeking Alpha →
- Upgrade to Buy after selloff
- Guidance cut, buybacks paused
- Housing bottom within 6 months
- 2027 construction growth 0-5%
Read on Seeking Alpha →
- Beat top + bottom line
- Computing: 10 straight growth quarters
- +20% YTD, 12x forward earnings
Read on Seeking Alpha →
- Buy: self-help turnaround
- $60M cost savings by 2028
- 9.3x EV/EBITDA vs Domino's premium
Read on Seeking Alpha →
- Buy, $56 fair value
- CLM volume +132% YoY
- EBITDA margin 54.6%
- 80% of loans off balance sheet
Read on Seeking Alpha →
- Down 50%+ since IPO
- Upgrade to Neutral
- High-teen EBITDA margins
- Watch ~3x leverage
Read on Seeking Alpha →
- Buy: ClearanceJobs momentum
- CJ = 59% of EBITDA
- AI job postings surging
- Buybacks + declining leverage
Read on Seeking Alpha →
- 9 of 16 pharma at 52-wk highs
- Q2 strength + rotation to healthcare
- Sanofi, AstraZeneca out of favor
- 4 healthcare ETFs compared
Read on Seeking Alpha →
- New pricing measures due today
- Big Pharma MFN deals done
- Mid-cap biotechs at risk
- Picks: Ionis, Supernus, United Therapeutics
Read on Seeking Alpha →
- Strong Buy -> Hold
- 2026 guidance cut
- PDUFA date Dec 3
- STELLAR-304 readout 2H26
Read on Seeking Alpha →
- Pivot to immunology (IBD)
- Phase 1: clean safety, 3.7% ADA
- Funded into 2029
- Quarterly dosing potential
Read on Seeking Alpha →
- Buy: strong Q2, low leverage
- 74% of Q4 days open to spot
- Hormuz/Red Sea = longer voyages
- Trading near NAV
Read on Seeking Alpha →
- US solar manufacturing buildout
- Q2 revenue ~2x YoY, 19.5% GM
- Still unprofitable
- Hold pending G2 ramp
Read on Seeking Alpha →
- Reliance-led data center buildout
- Value capture stays with hyperscalers
- INDY rated Sell: fees, bank weight
Read on Seeking Alpha →
- Drought + feed costs + screwworm
- Herd rebuild takes 3 years
- 2026 production -4% YoY (USDA)
Read on Seeking Alpha →
- CA wildfire law hits PCG, EIX
- Shein slides post-IPO
- Airbnb cuts fees for select hosts
Read on Seeking Alpha →
- Healthcare: diversification from AI
- 2027 sector earnings +22% YoY
- 3 quant picks post earnings beats
Read on Seeking Alpha →
- HY = managed, global income market
- 'Junk bond' label outdated
- Update mental labels with new data
Read on Seeking Alpha →
- Hold: margin pressure
- Weak demand + pricing
- 2027 guide: flat revenue
Read on Seeking Alpha →
- Speculative Buy
- Take 5 drives growth
- Low P/E misleading with debt
- Needs FCF + deleveraging
Read on Seeking Alpha →